Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases Eisai Jun 24, 2022 10:55 HKT/SGT Read More
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal Eisai Jun 22, 2022 13:05 HKT/SGT Read More
Fujitsu and Salesforce Japan start collaboration on healthcare solutions for the Japan market Fujitsu Ltd Jun 21, 2022 09:56 HKT/SGT Read More
SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development DIA Jun 15, 2022 09:30 JST Read More
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting Eisai Jun 06, 2022 14:05 HKT/SGT Read More
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting Eisai Jun 03, 2022 15:37 HKT/SGT Read More
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 Eisai May 27, 2022 11:49 HKT/SGT Read More
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS Eisai May 27, 2022 11:24 HKT/SGT Read More
エーザイ、メコバラミンの高用量製剤がALSの病態及び機能障害の進行抑制を予定される効能又は効果として、厚生労働省より希少疾病用医薬品に指定 Eisai May 27, 2022 10:00 JST Read More
Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI Fujitsu Ltd May 17, 2022 10:32 HKT/SGT Read More
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory Agilex Biolabs May 12, 2022 16:00 JST Read More
Hitachi High-Tech and Invivoscribe Partner to Advance Molecular Diagnostics Hitachi, Ltd. May 10, 2022 14:18 HKT/SGT Read More
